Biomimetics,
Journal Year:
2024,
Volume and Issue:
9(10), P. 645 - 645
Published: Oct. 20, 2024
Nanomedicine,
leveraging
the
unique
properties
of
nanoparticles,
has
revolutionized
diagnosis
and
treatment
neurological
diseases.
Among
various
nanotechnological
advancements,
ultrasound-mediated
drug
delivery
using
micro-
nanobubbles
offers
promising
solutions
to
overcome
blood-brain
barrier
(BBB),
enhancing
precision
efficacy
therapeutic
interventions.
This
review
explores
principles,
current
clinical
applications,
challenges,
future
directions
systems
in
treating
stroke,
brain
tumors,
neurodegenerative
diseases,
neuroinflammatory
disorders.
Additionally,
ongoing
trials
potential
advancements
this
field
are
discussed,
providing
a
comprehensive
overview
impact
nanomedicine
on
Journal of Clinical Medicine,
Journal Year:
2025,
Volume and Issue:
14(2), P. 386 - 386
Published: Jan. 9, 2025
The
blood-brain
barrier
(BBB)
is
a
crucial
structure
that
maintains
brain
homeostasis
by
regulating
the
entry
of
molecules
and
cells
from
bloodstream
into
central
nervous
system
(CNS).
Neurodegenerative
diseases
such
as
Alzheimer's
Parkinson's
disease,
well
ischemic
stroke,
compromise
integrity
BBB.
This
leads
to
increased
permeability
infiltration
harmful
substances,
thereby
accelerating
neurodegeneration.
In
this
review,
we
explore
mechanisms
underlying
BBB
disruption,
including
oxidative
stress,
neuroinflammation,
vascular
dysfunction,
loss
tight
junction
integrity,
in
patients
with
neurodegenerative
diseases.
We
discuss
how
breakdown
contributes
neurotoxicity,
abnormal
accumulation
pathological
proteins,
all
which
exacerbate
neuronal
damage
facilitate
disease
progression.
Furthermore,
potential
therapeutic
strategies
aimed
at
preserving
or
restoring
function,
anti-inflammatory
treatments,
antioxidant
therapies,
approaches
enhance
integrity.
Given
role
neurodegeneration,
maintaining
its
represents
promising
approach
slow
prevent
progression
Fluids and Barriers of the CNS,
Journal Year:
2023,
Volume and Issue:
20(1)
Published: Nov. 28, 2023
The
blood-brain
barrier
(BBB)
is
a
selectively
permeable
membrane
that
separates
the
bloodstream
from
brain.
While
useful
for
protecting
neural
tissue
harmful
substances,
brain-related
diseases
are
difficult
to
treat
due
this
barrier,
as
it
also
limits
efficacy
of
drug
delivery.
To
address
this,
promising
new
approaches
enhancing
delivery
based
on
disrupting
BBB
using
physical
means,
including
optical/photothermal
therapy,
electrical
stimulation,
and
acoustic/mechanical
stimulation.
These
mechanisms
can
temporarily
locally
open
BBB,
allowing
drugs
other
substances
enter.
Focused
ultrasound
particularly
promising,
with
ability
focus
energies
targeted,
deep-brain
regions.
In
review,
we
examine
recent
advances
in
temporary
disruption,
describing
their
underlying
well
evaluating
utility
these
regard
potential
risks
limitations.
methods
have
demonstrated
safety,
comparative
efficacy,
practicality
clinical
use
remain
an
ongoing
topic
research.
Frontiers in Aging Neuroscience,
Journal Year:
2023,
Volume and Issue:
15
Published: Feb. 16, 2023
The
existence
of
a
selective
blood-brain
barrier
(BBB)
and
neurovascular
coupling
are
two
unique
central
nervous
system
vasculature
features
that
result
in
an
intimate
relationship
between
neurons,
glia,
blood
vessels.
This
leads
to
significant
pathophysiological
overlap
neurodegenerative
cerebrovascular
diseases.
Alzheimer's
disease
(AD)
is
the
most
prevalent
whose
pathogenesis
still
be
unveiled
but
has
mostly
been
explored
under
light
amyloid-cascade
hypothesis.
Either
as
trigger,
bystander,
or
consequence
neurodegeneration,
vascular
dysfunction
early
component
pathological
conundrum
AD.
anatomical
functional
substrate
this
degeneration
BBB,
dynamic
semi-permeable
interface
consistently
shown
defective.
Several
molecular
genetic
changes
have
demonstrated
mediate
BBB
disruption
isoform
ε4
Apolipoprotein
E
at
same
time
strongest
risk
factor
for
AD
known
promoter
dysfunction.
Low-density
lipoprotein
receptor-related
protein
1
(LRP-1),
P-glycoprotein,
receptor
advanced
glycation
end
products
(RAGE)
examples
transporters
implicated
its
due
their
role
trafficking
amyloid-β.
currently
devoid
strategies
change
natural
course
burdening
illness.
unsuccess
may
partly
explained
by
our
misunderstanding
inability
develop
drugs
effectively
delivered
brain.
represent
therapeutic
opportunity
target
itself
vehicle.
In
review,
we
aim
explore
including
background
detail
how
it
can
targeted
future
research.
Advanced Drug Delivery Reviews,
Journal Year:
2024,
Volume and Issue:
208, P. 115274 - 115274
Published: March 6, 2024
Ultrasound
enhances
drug
delivery
into
the
central
nervous
system
(CNS)
by
opening
barriers
between
blood
and
CNS
triggering
release
of
drugs
from
carriers.
A
key
challenge
in
translating
setups
vitro
to
vivo
settings
is
achieving
equivalent
acoustic
energy
delivery.
Multiple
devices
have
now
been
demonstrated
focus
ultrasound
brain,
with
concepts
emerging
also
target
spinal
cord.
Clinical
trials
date
used
facilitate
blood–brain
barrier.
While
most
focused
on
feasibility
safety
considerations,
therapeutic
benefits
are
beginning
emerge.
To
advance
translation
these
technologies
for
applications,
researchers
should
standardise
exposure
protocol
fine-tune
parameters.
Computational
modelling
be
increasingly
as
a
core
component
develop
both
delivering
accurate
reproducible
CNS.
This
field
holds
promise
transformative
advancements
management
pharmacological
treatment
complex
challenging
disorders.
Neurochemical Research,
Journal Year:
2025,
Volume and Issue:
50(1)
Published: Jan. 3, 2025
Abstract
Huntington’s
disease
(HD)
is
a
progressive
neurodegenerative
resulting
from
mutation
in
the
huntingtin
(HTT)
gene
and
characterized
by
motor
dysfunction,
cognitive
decline,
psychiatric
disturbances.
Currently,
no
disease-modifying
treatments
are
available.
Recent
research
has
developed
therapeutic
agents
that
may
have
potential
to
directly
target
pathology,
such
as
silencing
or
clearing
mutant
protein.
However,
these
limited
their
inability
cross
blood-brain
barrier
(BBB),
preventing
optimal
effects.
Although
various
techniques
been
explored
overcome
BBB,
focused
ultrasound
(FUS)
emerged
promising
non-invasive
modality
offering
for
targeted
intervention
diseases,
including
HD.
Preclinical
studies
demonstrated
safety
efficacy
of
FUS
delivering
agents,
siRNAs
AAV
vector-based
therapy,
significant
reductions
HTT
expression
improvements
function
HD
mouse
models.
Furthermore,
profile
FUS-induced
BBB
opening
established
clinical
trials
on
human
patients
diseases
other
than
HD,
showing
adverse
effects
brain
structure
function.
This
review
provides
comprehensive
overview
current
state
connects
existing
evidence
with
its
promise
establishing
therapies
Graphical
Gastrointestinal Disorders,
Journal Year:
2024,
Volume and Issue:
6(2), P. 380 - 401
Published: April 13, 2024
Traditional
cancer
treatments
have
not
significantly
improved
the
survival
rates
for
individuals
with
colorectal
cancer.
As
a
result,
there
is
dire
need
to
explore
novel
treatment
modalities
that
can
target
cancer-specific
niches,
transform
cold
tumors
into
hot
ones,
and
disrupt
tumor
niche.
Therapeutic
focused
ultrasound,
recognized
its
capacity
induce
thermal
mechanical
impacts
on
tissue,
potentially
eliminate
cells
elicit
body’s
anticancer
reaction
by
disrupting
microenvironment.
This
article
provides
an
overview
of
recent
developments
in
employing
therapeutic
ultrasound
(TFUS)
enhance
natural
defenses
against
cancers.
It
also
discusses
studies
examining
utility
TFUS
treating
patients
research
indicating
potential
stimulate
response
various
vitro
vivo
models.
Furthermore,
it
explores
effects
immune
system
highlights
safety
effectiveness
managing
cancer,
providing
relief
from
pain,
improving
rates.
Given
indications
may
bolster
augment
therapy
clinical
preclinical
models,
has
emerge
as
pivotal
tool
settings.
Theranostics,
Journal Year:
2022,
Volume and Issue:
12(16), P. 6826 - 6847
Published: Jan. 1, 2022
Rationale:The
blood-brain
barrier
(BBB)
is
a
major
impediment
to
therapeutic
intracranial
drug
delivery
for
the
treatment
of
neurodegenerative
diseases,
including
Alzheimer's
disease
(AD).Focused
ultrasound
applied
together
with
microbubbles
(FUS
+MB
)
novel
technique
transiently
open
BBB
and
increase
delivery.Evidence
suggests
that
FUS
safe,
however,
effects
on
human
cells,
especially
in
context
AD,
remain
sparsely
investigated.In
addition,
there
currently
are
no
cell
platforms
test
-mediated
delivery.Methods:
Here
we
generated
cells
(induced
brain
endothelial-like
(iBECs)
astrocytes
(iAstrocytes))
from
apolipoprotein
E
gene
allele
E4
(APOE4,
high
sporadic
AD
risk)
E3
(APOE3,
lower
carrying
patient-derived
induced
pluripotent
stem
(iPSCs).We
established
mono-and
co-culture
models
control
investigate
phenotype
screen
two
potentially
antibodies,
an
Aducanumab-analogue
(Aduhelm
TM
;
anti-amyloid-β)
anti-Tau
antibody,
RNF5.We
then
developed
hydrogel-based
2.5D
model
as
step
towards
more
physiologically
relevant
platform.Results:
When
compared
untreated
RNF5
was
significantly
increased
(up
1.73
fold),
across
Transwell-based
following
treatment.Our
results
also
demonstrated
safety
indicated
by
minimal
changes
iBEC
transcriptome
well
little
or
iAstrocyte
viability
inflammatory
responses
within
first
24
h
post
.Furthermore,
successful
formation
our
(1.4
fold)
.Conclusion:
Our
demonstrate
robust
reproducible
approach
utilize
patient
screening
vitro.With
such
platform
research
previously
not
reported,
it
has
potential
identify
-deliverable
drugs
cell-and
patient-specific
,
accelerating
use
modality
AD.
Pharmaceutics,
Journal Year:
2022,
Volume and Issue:
14(10), P. 2231 - 2231
Published: Oct. 19, 2022
Despite
significant
advances
in
developing
drugs
to
treat
brain
tumours,
achieving
therapeutic
concentrations
of
the
drug
at
tumour
site
remains
a
major
challenge
due
presence
blood–brain
barrier
(BBB).
Several
strategies
have
evolved
enhance
delivery
chemotherapeutic
agents
tumours;
however,
most
approaches
several
limitations
which
hinder
their
clinical
utility.
Promising
studies
indicate
that
ultrasound
can
penetrate
skull
target
specific
regions
and
transiently
open
BBB,
safely
reversibly,
with
high
degree
spatial
temporal
specificity.
In
this
review,
we
initially
describe
basics
ultrasound,
then
detail
ultrasound-based
mechanisms
by
improve
therapy.
We
review
pre-clinical
findings
from
ultrasound-mediated
BBB
opening
outline
current
devices
technologies
designed
for
purpose.